Excretion of OLS and sodium were maximal on day 5 and lowest on days 9 and 10. Urine excretion of OLS on day 5 (2.66 ± 1.22 nmol/24 h) was significantly higher (P <0.0001) than on day 10 (1.47 ± 0.69 nmolJ24 h). We conclude that (a) the assay developed has sufficient sensitivity and specificity to detect endogenous OLS present in biological fluids, and (b) salt intake increases the excretion of OLS.
endogenous inhibitor . hypertension#{149} sodium #{149} potassium
#{149} ATPase
The presence of endogenous sodium transport inhibitor(s) in several species including humans is well documented [1] [2] [3] [4] . This sodium transport inhibitor (s) has been suggested to play a role in the regulation of sodium excretion and in the pathogenesis of hypertension.
Increased concentrations of sodium transport inhibitor (s) have generally been found during plasma volume expansion, during high salt intake, and in hypertension [1] [2] [3] [4] [5] [8] . An immunoassay for ouabain was developed and the presence of ouabain in human plasma was demonstrated [9] . However, Doris et al. [JO] and Lewis et al. [11] were not able to demonstrate the presence of endogenous ouabain or ouabainlike substance (OLS) in human plasma.' The low specificity of the antibody used in these studies may account for these results.
The aim of this study was to develop a specific and sensitive immunoassay for ouabain and to examine the effect of salt loading on the excretion of OLS in healthy subjects.
Materials and Methods

MATERIALS
Unless otherwise stated, chemicals and reagents were Analar grade and purchased from Sigma Chemical Co (St. Louis, MO). Dextran grade C, Mr 60 000 -90 000, and methanol were from BDH (Poole, UK), and [21,22-3H] KLH (34.5 mg) was dissolved in 20 mL of deionized water and the pH was adjusted to 9.5 with 0.36 mol/L K2C03.
The periodate-oxidized ouabain mixture was added dropwise to the protein solution with continuous magnetic stirring. The pH was maintained in the 9.3-9.5 range by simultaneous dropwise addition of 0.36 mol/L K,CO.
After the pH had stabilized in the 9.3-9.5 range, 7.9 mmol of sodium borohydride (freshly prepared in 20 mL of distilled water) was added to the mixture. The reaction mixture was transferred to a conical flask and left overnight at room temperature.
The following morning the pH was adjusted to 6.5 with I mol/L ammonium hydroxide and dialyzed overnight against cold running tap water. The contents of the dialysis tube were lyophilized.
A I g/L solution of the lyophilisate was prepared in distilled water and the protein content determined. Aliquots (50 1iL) were also taken for counting to determine the radioactivity (dpin) associated with the lyophilisate.
The mass of ouabain represented by the radioactivity (dpm) was calculated from the specific activity of the original material. From this we estimated that the KLH conjugate had 493 mol of ouabain per mol of KLH.
2) Ouabain-succinyl dihydrazide (SDH)-ovalbumin (OVA) conjugate:
Conjugation of ouabain to OVA was carried out as described by Harris et al. [9] . One gram of SDH and 215 mg of OVA were added to water, pH 5, containing 3.5 mmol of 1-(3-dimethylaminopropyl)-3-ethyl carbodiimide (EDAC). The mixture was stirred for 20 h at room temperature, after which it was dialyzed four times against 5 L of 49 mmol/L sodium acetate buffer, pH 4.5 at 4#{176}C over 72 h. Ouabain (0.9 19 mmol) was dissolved in 6.7 mL of water and 4.5 mL of acetone, and 92.5 kBq of [3Hlouabain was added. The mixture was warmed gently to dissolve ouabain. On cooling to room temperature 2.3 mmol of sodium periodate was added. After 30 mm, 3 mmol K,HPO4 was added over 5 h to raise the pH. The reaction was quenched overnight by the addition of 0.4 mmol of mesoerythritol.
The acetone/water containing the dialdehyde was dried and OVA-SDH dialysate was added to it. The total volume was brought up to 25 mL with 30 mmol/L K2HPO4 and to a pH of 7. After 30 mm, 1.1 mmol of sodium borocyanohydride (NaBH, CN) was added and the mixture was stirred continuously. A further 2.7 mmol of NaBH,CN was added 90 mm later. After 20 h the mixture was dialyzed for 72 h against 25 mmol/L Tris buffer, pH 7.9, before being lyophilized.
Determination of protein and associated radioactivity, as described earlier, indicated 27 mol of ouabain per mol of OVA.
Immunization.
Ouabain conjugated
to OVA was dissolved in 15 mmol/L NaCl at a concentration of 2 g/L and mixed with equal volumes of Freund's incomplete adjuvant, and four goats were immunized.
Four weeks later, the goats were boosted with KLH-ouabain in Freund's incomplete adjuvant. Two weeks after the last injection, the goats were bled; serum was separated and stored at -70 #{176}C. Antiserum with the best titer was selected for RIA. Precision and analytical recoveiy. Ouabain at different concentrations (0.2, 2, 4, 5, 8, or 10 nmol/L) was added to buffer or urine samples and each sample was extracted and assayed to determine recovery of the whole assay procedure.
Intraassay precision was determined by analyzing a urine sample 10 times and interassay precision was determined by analyzing urine samples with and without added ouahain in 10 different assays.
Parallelism. Urine (30 mL) from a healthy volunteer was extracted and reconstituted in 3 mL of assay buffer. The concentrated extract was subsequently serially diluted and assayed. The above experiment was also repeated with a urine sample with added ouabain to increase the concentration by 10 nmol/L. 
SALT
LOADING STUDIES
Subjects. To determine the effects of increased salt intake on excretion of OLS, 10 healthy male volunteers (ages 18-22 years) took part in a 10-day salt loading study. The volunteers had no history of hypertension, and were not taking any medication. On days 1 to 5 inclusive, subjects were given 200 mmol of additional sodium as slow-release sodium tablets (Slow Sodium, Ciba, UK). On days 6-10, subjects were placed on a low-sodium diet (<40 mmol Na/day). This study was approved by the Ethical Committee of the hospital. During the entire study period subjects were allowed to drink fluids ad lib. All urine passed over the entire study period was collected for the measurement of sodium, potassium, creatinine, and OLS. Urinary sodium and potassium concentrations were measured by flame photometry, and urinary creatinine concentrations were measured by a standard Jaffe reaction in an automated analyzer. Urinary OLS was measured by RIA as described above.
Statistics. The data are expressed as means ± SE and were analyzed by using analysis of variance for repeated measurements. Scheff#{233}'s comparisons were performed on the means, and P 0.05 was considered significant.
Results
Titer. The antisera obtained were of high titer and the antibody dilution required to bind 50% of the tracer ([21,22-3H]ouabain) was 1:200 000. Calibration curve. Fig. 1A shows a typical calibration curve for ouabain.
Serial dilutions of a urine extract produced a curve parallel to the ouabain calibration curve (Fig. 1A) , as did urine with added ouabain (10 nmolJL) (Fig. IB) .
Sensitivity. The detection limit of the assay, defined as 2 SD from the mean for the zero calibrator, was calculated as 0.06 nmol/L from 10 experiments. Table I shows the cross-reactivity of the antibody against some cardiac glycosides and related compounds. Their cross-reactivity was determined by comparison with a ouabain calibration curve (Fig. 2) cortisol, 17-a-hydroxyprogesterone, and androstenedione showed negligible cross-reactivity, indicating that the antiserum is highly specific for ouabain.
Specficity.
Recovery studies and precision. Extraction recoveries of added [2l,22,-3H]ouabain
to urine or buffer were 90-107% and 90-103%, respectively. Recovery of cold ouahain was determined by adding ouabain to urine treated with charcoal to remove endogenous ouabain. Extraction and subsequent assay of these samples demonstrated that recovery ranged from 75% to 97.8% over the range of 0.2-10 nmolfL (Table 2 ). Precision data are also shown in Table 2 . The intraassay CV was between 4.5% and 5.9% and interassay CV was between 6.5% and 7.7%.
Effect ofsalt loading on the excretion of sodium and ouabain. Table 3 shows sodium excretion; OLS excretion; urine volume; and sodium/creatinine, OLS/creatinine, and sodium/potassium ratios during the salt-loading study. Sodium excretion increased from 280 ± 55 mmol/day on day 1 to 419 ± 91 on day 3 and remained high on days 4 and 5. On low salt, sodium excretion rapidly decreased and on day 10 was 25 ± 20 mmol/day. 5 and 4 was significantly higher than on days 1 and 2 (P <0.05 by Scheff#{233}'s test). The maximal excretion of both sodium and OLS occurred on day 5. From day 6, OLS excretion decreased rapidly and by day 10 was 48.8% lower than on day 5. This trend was highly significant (by ANOVA, F = 6.53, P <0.0001). Excretion of OLS on days 7 to 10 was significantly lower than on day 5 (P <0.05). To exclude any effect due to changes in water excretion and to exclude possible incomplete urine collections, OLS excretion was also expressed as OLS/creatinine ratio ( Table 3) . OLS/creatinine ratio also showed a similar trend. dayS to 0.17 ± 0.05% on day 10 (P <0.001). Excretion of OLS increased from 2.11 ± 0.83 nmol/day on day 1 to 2.66 ± 1.22
nmol/day on day 5 ( Fig. 3 , Table 3 ). This trend was significant (by ANOVA, F = 3.23, P <0.02 3), and OLS excretion on days 
Discussion
Much evidence has accumulated
about the role of a sodium transport inhibitor in the regulation of sodium balance in humans and in other mammals [1] [2] [3] [4] .
The nature of this substance has been elusive. Hamlyn et al. [8] identified this endogenous sodium transport inhibitor as ouabain or OLS. However, the reported circulating concentrations of OLS in humans vary widely, from 0.076 to 1.1 nmolIL [13] .
Some of this variation in concentration of OLS appears to be due to the specificity of the antibody. The antiserum selected in this study was of a high titer (200 000) and showed a high degree of specificity for ouabain, with little or no appreciable crossreactivity with other structurally related compounds (Table I) ; antisera used by other investigators showed variable degrees of cross-reactivity with structurally related compounds. Table 4  compares the immunoassays described so far. The antiserum used by Lewis et al. [11] showed high cross-reactivity with ouabagenmn (77.2%) and strophanthidin (70.4%). The antisera developed by Harris et al. [9] showed cross-reactivity for strophanthidin (66%), ouabagenin (40%), digitoxin (28%), and digoxin (5.2%). Antiserum used by Doris [14] also showed significant cross-reactivity with ouabagenin (56.2%) and digoxin (4.5%). More recently, Komiyatna et al. [16] for strophanthidin, digitoxin, and ouabagenin, being almost the same as ouabain in their ELISA system. Antisera produced by Masugi et al. [18] was not sufficiently characterized, and ouabain-like immunoreactivity was not specific because of an unstable peroxide. Our antisera showed high specificity to ouabain, and cross-reactivity with ouabagenin (4%) was the lowest reported so far, with only Gomez-Sanchez et al. [17] reporting a lower value (2.2%) by ELISA.
The types of assays used by investigators for ouabain measurement also vary. Initially, we developed an ELISA method (Table 2) , whereas recovery of [21, in urine or buffer was consistently >90%. Dilution of a urine extract yielded a curve with slopes similar to the ouabain calibration curve, and urine samples with added ouahain gave a curve superimposable on the ouabain calibration curve. Studies of cligoxin-like factor(s) suggest that there may be conjugated forms present in urine f7J. To investigate this in preliminary studies, we examined the effect of treatment of urine with glucuronidase on OLS activity and found that there appeared to be some conjugated OLS (Butt et al.; unpublished observation) . Further studies are in progress to quantify the conjugated form of OLS. When compared with immunoassays used by other investigators (Table 4) , our anti-ouabain antiserum was not only the most extensively characterized, but also proved to have the highest degree of specificity for ouabain. The sensitivity of the assay was comparable with both the ELISA and RIA methods described by others.
With a variety of techniques, increased concentrations of sodium transport inhibitor have been found during volume expansion /21, 221, during high salt intake [5, 231, and in hypertension / 24, 25] . As far as we are aware there have been no studies on the effect of salt intake on excretion of OLS measured by an immunoassay. Although existing evidence suggests that there is a relation between sodium and OLS excretion during salt loading, most of the data were obtained from animal experiments. The results presented here (Table 3 and Fig. 3) show that excretion of OLS is increased during high salt intake.
It has l)een suggested that increased excretion of sodium transport inhibitors could be the result of increased urine volume /26/. To exclude this possibility we expressed the excretion of OLS in relation to creatinine (Table 3 ) and found similar changes. Furthermore, during acute water loading, the excretion of OLS did not change significantly /27/.
